333 related articles for article (PubMed ID: 26177051)
1. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
Leontieva OV; Demidenko ZN; Blagosklonny MV
Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
[TBL] [Abstract][Full Text] [Related]
2. Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect.
Sousa-Victor P; García-Prat L; Muñoz-Cánoves P
Oncotarget; 2015 Sep; 6(27):23052-4. PubMed ID: 26375366
[TBL] [Abstract][Full Text] [Related]
3. Gerosuppression by pan-mTOR inhibitors.
Leontieva OV; Blagosklonny MV
Aging (Albany NY); 2016 Dec; 8(12):3535-3551. PubMed ID: 28077803
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin, proliferation and geroconversion to senescence.
Blagosklonny MV
Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
[TBL] [Abstract][Full Text] [Related]
5. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.
Leontieva OV; Blagosklonny MV
Oncotarget; 2014 Dec; 5(24):12715-27. PubMed ID: 25587030
[TBL] [Abstract][Full Text] [Related]
6. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
7. MEK drives cyclin D1 hyperelevation during geroconversion.
Leontieva OV; Demidenko ZN; Blagosklonny MV
Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia suppresses conversion from proliferative arrest to cellular senescence.
Leontieva OV; Natarajan V; Demidenko ZN; Burdelya LG; Gudkov AV; Blagosklonny MV
Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13314-8. PubMed ID: 22847439
[TBL] [Abstract][Full Text] [Related]
9. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
[TBL] [Abstract][Full Text] [Related]
10. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
Leontieva OV; Blagosklonny MV
Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
[TBL] [Abstract][Full Text] [Related]
11. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
Ravichandran K; Zafar I; Ozkok A; Edelstein CL
Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
[TBL] [Abstract][Full Text] [Related]
12. Cell senescence, rapamycin and hyperfunction theory of aging.
Blagosklonny MV
Cell Cycle; 2022 Jul; 21(14):1456-1467. PubMed ID: 35358003
[TBL] [Abstract][Full Text] [Related]
13. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107.
Khor ES; Wong PF
Int J Biochem Cell Biol; 2018 Aug; 101():64-73. PubMed ID: 29857052
[TBL] [Abstract][Full Text] [Related]
14. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
Gordeev SA; Bykova TV; Zubova SG; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
Oncotarget; 2015 Dec; 6(42):44905-26. PubMed ID: 26636543
[TBL] [Abstract][Full Text] [Related]
15. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
16. S6K in geroconversion.
Leontieva OV; Demidenko ZN; Blagosklonny MV
Cell Cycle; 2013 Oct; 12(20):3249-52. PubMed ID: 24036549
[TBL] [Abstract][Full Text] [Related]
17. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
[TBL] [Abstract][Full Text] [Related]
18. Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo.
Zhang J; Jiang W; Liu W; Wu JJ; Song L; Cheng JX; Yao M; Yang LP; Yao DF
Future Oncol; 2016 Feb; 12(4):515-24. PubMed ID: 26776341
[TBL] [Abstract][Full Text] [Related]
19. From rapalogs to anti-aging formula.
Blagosklonny MV
Oncotarget; 2017 May; 8(22):35492-35507. PubMed ID: 28548953
[TBL] [Abstract][Full Text] [Related]
20. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
